Amphastar Director Sells 16,679 Shares for $441,800

Amphastar director Floyd Petersen exercised 16,679 fully vested options at $16.69 and immediately sold the resulting shares at about $26.49 on Nov. 13, 2025, generating roughly $441,800 while retaining 75,531 shares (~$2.0M post-transaction). Amphastar (market cap ~$1.20B) reported TTM revenue of $723.31M and net income of $111.63M; the stock was down ~42% year-over-year at the trade date but has seen recent lift after FDA approval of a teriparatide prefilled pen that is bioequivalent to Eli Lilly’s Forteo. The company also maintains an active buyback program (14.1M shares repurchased for ~$369.1M since 2016), a factor that can offset option dilution and influence investor perception following insider option exercises.

Analysis

Market structure: Amphastar (AMPH) is positioned to benefit if its newly FDA‑approved teriparatide pen wins institutional contracts — hospitals and payors who buy lower‑cost generics are clear winners; incumbent brand owner LLY is the direct loser if price competition intensifies. Vertical integration (in‑house API) gives AMPH a supply‑cost advantage versus pure CMOs, supporting margin resilience even if selling prices drop; a 42% YTD stock decline implies a >25–35% multiple compression vs peers despite ~15% net margin (111.6/723.3).

Risk assessment: Tail risks include an FDA inspection failure or product liability recall that could wipe out near‑term earnings and push stock >40% lower; reimbursement/contracting setbacks are medium‑probability, high‑impact events. Immediate (days) impact from the Form‑4 is negligible; short term (0–6 months) is driven by teriparatide uptake and Q4 revenue prints; long term (12+ months) depends on market share vs Forteo and sustainable ASPs. Hidden drivers: buybacks have masked dilution from option programs and will matter if management slows repurchases.

Trade implications: Tactical trades include a modest directional long in AMPH sized 1–3% of portfolio financed by selling less efficient small‑cap biotech exposure; use defined‑risk option spreads to cap downside (see decisions). Pair trade idea: long AMPH / short LLY to isolate generic uptake risk over 6–12 months. Time entries on either a pullback to <$22 or after two consecutive quarters showing teriparatide unit growth >10% QoQ.

Contrarian angles: The market treats the director’s exercise as a negative but it’s routine option monetization — only a 4% realized reduction since May 2024 — and management’s large $369m buyback history argues for balance‑sheet support. If AMPH captures even 10–20% of Forteo within 12 months, revenue upside is underpriced; conversely, aggressive share‑taking could trigger margin compression (watch for >300bp gross margin decline).

Key Decisions for Investors

• Establish a 2% long position in AMPH at or below $28 (size 2% of portfolio NAV), target price $40 in 12 months (~+43% from $28), hard stop‑loss at $21 (≈‑25%) to limit tail loss.
• Execute a defined‑risk options trade instead of outright stock: buy AMPH Jan 2027 25C and sell Jan 2027 40C (ratio 1:1) sizing notionally equal to 1% of portfolio; this caps max loss and offers asymmetric upside if teriparatide uptake accelerates.
• Implement a pair trade to de‑risk macro: go long $1 of AMPH and short $0.6 of LLY (dollar‑neutral approx) — target to close after 6–12 months or when AMPH outperforms LLY by 15%; rationale: capture generic share flow versus incumbent brand risk.
• Risk‑management trigger: if quarterly gross margin falls >300 bps QoQ or FDA posts a Form 483 for Amphastar, reduce AMPH exposure by 50% within 5 trading days and buy protective puts (6‑month, ~20% OTM).